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ABSTRACT
This is a concise review of the uses of botulinum
toxins (BTXs) in dermatology and cosmetic
procedures. It is a clinical rather than a basic
science, pharmacological review. BTX had been
initially used for selectively reducing and
balancing periorbital muscle activity; thereby,
reducing childhood strabismus and
blepharospasm. This clinical research was
initiated by Dr. Alan Scott over 40 years ago.
BTX type A (BTX-A) was serendipitously
observed to reduce forehead frown lines in
patients being treated for blepharospasm.
Extensive clinical research and development
resulted in widespread aesthetic uses for BTX-A
by reduction of selected hyperfunctional facial
muscles. BTXs are also used for reduced
localized hyperhidrosis. A topical BTX-A is
being developed as a potential alternative to
injected BTX.
Keywords: Axillary hyperhidrosis; Botulinum
toxins; Combination treatment; Dermatology;
Facial lines; Periocular muscles; Strabismus
INTRODUCTION
The first medical use of botulinum neurotoxin
(BTX) was described by Dr. Alan Scott during
the 1970s, when BTX type A (BTX-A) was used
for reducing over-activity of selected periocular
muscles in patients with strabismus [1, 2].
Following this observation, BTXs have been
increasingly studied for a wide variety of other
therapeutic and aesthetic uses. In the late
1980s, Drs. Jean and Alastair Carruthers
observed a reduction of dynamic lines on
the forehead of a patient being treated
for blepharospasm. They reported their
observation in 1992 [3]. Double-blind,
placebo-controlled studies using BTX-A for
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upper facial lines in the USA confirmed their
reduction of lower forehead lines for
approximately 4 months [4, 5].
These initial observations were followed by
double-blind, placebo-controlled studies of
several hundred patients in the USA, which
demonstrated that BTX-A was safe and effective
for reducing the severity of glabellar (lower
forehead vertical frown lines) [6, 7].
A significant improvement was observed a
few days after treatment and the mean
duration of treatment was in excess of
4 months. This study utilized appropriate
doses of onabotulinumtoxinA, with a total of
20 onabotulinumtoxinA units for the lower
forehead frown lines. Other studies confirmed
that BTX-A is also effective for lateral periorbital
lines [8], infraorbital lines [9], nasal lines,
terional area, the jaw line, and the platysma.
BTXS
There are two main serotypes of BTXs that are
used clinically; the most commonly used being
BTX-A. BTX type B (BTX-B) has a much shorter
duration of effect than BTX-A, but is
occasionally used if therapeutic resistance to
BTX-A is observed [10]. BTX-A and -B are also
effective at reducing sweating in areas such as
the axillae [11, 12]. BTX-A treatment for axillary
hyperhidrosis has been approved in numerous
countries in addition to the USA. A recent study
of hyperhidrosis found that the benefit of
duration of BTX-B was longer to that seen
after intramuscular treatment, but still less
than BTX-A [13].
The transport of the BTX-A is by rapid uptake
of the light chain of the toxin into the
neuromuscular junction, and the presynaptic
inhibition of acetylcholine release is thought to
be one mode of action of BTX-A (Fig. 1). As a
result, BTX-A results in localized, reversible
muscle relaxation (1). Some facial lines result
from repetitive contraction of facial muscles
and, as BTX-A reduces muscle action, one cause
of facial lines is, thus, reduced [4–7].
For the treatment of hyperhidrosis, BTX-A
activity is the result of the inhibition of the
release of acetylcholine, a neurotransmitter that
controls emotional, non-thermoregulatory
sweating [11, 12]. However, one of the
practical problems with BTX-A treatment is its
variable duration of benefit against
hyperhidrosis. Those patients that have a long
duration of benefit (i.e., 9 months or longer)
find the treatment worthwhile, whilst those
with short duration (i.e., 4 months or less) are
less inclined to continue.
FACIAL INJECTION SITES FOR BTX-A
The sites of injection used to improve facial
lines and, therefore, some signs of facial aging
are (Figs. 2, 3, 4, 5, 6, 7): (A) upper face:
horizontal forehead lines, vertical forehead
lines, supraorbital lines, periorbital (crow’s
feet) lines, infraorbital lines, and paranasal
lines [13]; (B) lower face: perioral lines, vertical
rhytids above the upper lip, and turning down
of the angles of the mouth (melomental folds)
from depressor angulae oris muscle; (C) vertical
neck bands produced by platysmal muscle
activity can also be reduced with BTX-A [14].
DIFFERENT TYPES OF BTX-A
Two different commercial types of BTX-A have
been available in Europe since the 1990s. The
two types are produced by different bacteria
with differing fermentation and purification
processes, and also have different potency and
diffusion. The dilution and dosing have been
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investigated, and estimated conversion ratios of
one type of BTX-A to the other have been
proposed [15, 16]. This has been purified by a
propriety process to remove inactive proteins.
More recently, incobotulinumtoxinA has been
available in Europe.
Side effects from BTX-A are local at doses used
for aesthetic indications, e.g., bruising, and brow
and/or eyelid ptosis. Side effects are usually the
result of inexpert injection of BTX-A, for
example, injections of too high a dose of BTX-A
to the lower lateral forehead may result in both
brow ptosis as well as upper eyelid ptosis.
Injections too low to the infraorbital area may
result in upper lip and lower facial ptosis. Facial
asymmetry may also occur; these side effects are
Fig. 1 Possible mode of action of BTX-A. BTX-A botulinum toxin type A, SNAP-25 synaptosomal-associated protein 25,
SNARE SNAP receptor, VAMP vesicle-associated membrane protein
Fig. 2 Onset of action of onabotulinumtoxinA Fig. 3 Onset of action of abobotulinumtoxinA
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usually temporary but can be of understandable
concern to patients [17]. Rare side effects include
headaches, paraesthesia, muscle and brow
‘‘heaviness,’’ diplopia, dry eyes, dysphagia, and
dysarthria. The physician injecting BTX-A
should be trained to try to avoid and correct
these problems.
Resistance to BTX-A is a rare problem and the
mechanism is unknown, but may involve
Fig. 4 Duration of beneﬁt of onabotulinumtoxinA can be
measured 6 months post-treatment
Fig. 5 Selection of toxin based on clinical features.
This patient has focal deep glabellar lines and requires
brow elevation. The patient was a good candidate for
onabotulinumtoxin A, which was given at 2 and 4 units
per site (910) resulting in a total of 32 units administered
Fig. 6 Selection of toxins based on clinical features. This
patient has a broad forehead, transverse lines but no brow
elevation is required. The patient was a good candidate for
abobotulinumtoxin A, which was given at 5 and 10 units
per site, resulting in a total of 115 units administered
Fig. 7 A lower facial indication for BTX-A. a This
patient had mentalis dimples for which 15 units of
abobotulinumtoxinA was administered to the mid
mentalis. b The same patient 4 weeks post-treatment.
BTX-A botulinumtoxinA
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antibodies blocking the uptake or action of
BTX-A. The incidence of acquired resistance is
currently not determined. BTX-B can be used in
cases of therapeutic resistance.
COMBINATION TREATMENTS
WITH BTX-A
Combination treatments are selected for
appropriate patients to rejuvenate the aging
face [17]. Examples of these combinations
include administration of BTX-A prior to laser
treatment with resurfacing lasers [17] or
fractionated lasers (Figs. 8, 9). BTX-A is ideally
delivered at least 1 week prior to laser
treatment, which enables the hyperactive
muscle action to be reduced; thereby, reducing
the cause of facial lines. In addition, as one
theory of skin rejuvenation with these laser
systems is the stimulation of neocollagenesis, it
is likely that less-folded skin following BTX-A
leads to more uniform neocollagenesis [18].
Other situations where combination
treatments are useful is the combination of
BTX-A and dermal fillers in problems such as
deep vertical lower forehead lines. Here, BTX-A
alone will improve, but not clear, the deep
furrows that are present in some patients. The
use of BTX-A plus temporary fillers can give a
more prolonged effect than using the filler alone
[19]. Similarly, the use of BTX-A to the upper lip
area together with a filler in the upper lip can
provide an adjunctive benefit to the correction
of upper lip lines. Dermal fillers and BTX-A can
also be combined in lower facial areas where the
BTX-A is injected into areas such as the
depressor angulae oris and mentalis muscles,
and the filler injected into melomental folds.
RECENT QUANTITATIVE STUDIES
OF BTX-A FOR FACIAL LINES
In the UK, onabotulinumtoxinA and
abobotulinumtoxinA have been used for
approximately 20 years. Results from
quantitative studies show that the onset
and duration of benefit is variable when
different BTXs are compared [20]. This is
not surprising, as different BTXs are individual
molecules with different molecular weights.
It has been shown that onabotulinumtoxinA
and abobotulinumtoxinA have similar
benefits, although in a recent study,
abobotulinumtoxinA was found to be slightly
(at a 1:3 ratio) more efficient than
onabotulinumtoxinA for crow’s feet [21].
Fig. 8 Combination of treatments: hyaluronic ﬁller in the
upper cheeks, lips; polylactic acid over the lower face;
BTX-A in the forehead, crow’s feet, and neck; fractional
laser treatment to the face and neck. BTX-A
botulinumtoxinA
Fig. 9 A summary of how to incorporate BTX-A in a
treatment program. BTX-A botulinum toxin A, IPL
intense pulsed light
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More recently, incobotulinumtoxinA has
been approved for dystonia. Further studies
are required to assess comparative
efficacies of incobotulinumtoxinA and
onabotulinumtoxinA. A recent study
suggested the equivalent efficacy of 1 unit
of onabotulinumtoxinA to 1 unit of
incobotulinumtoxinA; however, this was only
a 12 week study [22] and further comparisons
would be desirable.
DIFFERENT BTXS APPROVED
IN EUROPE AND USA
A comparison of molecular characteristics and
product approvals of BTXs can be seen in
Table 1, and myths and truths in Fig. 10.
TOPICAL BTX
Topical BTXs continue to be investigated
mainly in Mexico and North America. A novel
gel delivery system is also available, which
has been developed for delivering a 150 kDa
BTX-A formulation (developed by Revance
Therapeutics, Inc., Newark, CA, USA) Studies
have so far mainly focused on treating
axillary hyperhidrosis and crow’s feet
areas [23], with this formulation showing
effective and very promising results. Studies
comparing the efficiency and duration
compared with injectable BTX-A will be of
interest.
CONCLUSION
BTX-A is a safe and effective treatment for the
reduction of hyperfunctional facial muscles that
cause facial lines. In addition, it is also a
treatment option for the control of localized
hyperhidrosis.
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onabotulinumtoxinA A 900 *7 EU ? USA EU ? USA EU ? USA
abobotulinumtoxinA A 500–900 *7 EU ? USA No EU ? USA
incobotulinumtoxinA A 150 *7 EU No EU
rimabotulinumtoxinB B 700–900 5.6 No No EU ? USA
Fig. 10 Myths and truths of BTX-A. Abo-A
abobotulinumtoxinA, BTX-A botulinum toxin A, Ona-A
onabotulinumtoxinA
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